10.25
+0.74(+7.78%)
Currency In USD
| Previous Close | 9.51 |
| Open | 9.42 |
| Day High | 10.29 |
| Day Low | 9.42 |
| 52-Week High | 15.74 |
| 52-Week Low | 2.32 |
| Volume | 829,041 |
| Average Volume | 1.38M |
| Market Cap | 554.64M |
| PE | -8.99 |
| EPS | -1.14 |
| Moving Average 50 Days | 10.54 |
| Moving Average 200 Days | 7.63 |
| Change | 0.74 |
If you invested $1000 in Fulcrum Therapeutics, Inc. (FULC) since IPO date, it would be worth $759.26 as of January 14, 2026 at a share price of $10.25. Whereas If you bought $1000 worth of Fulcrum Therapeutics, Inc. (FULC) shares 5 years ago, it would be worth $903.08 as of January 14, 2026 at a share price of $10.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rar
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 10, 2025 12:48 PM GMT
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
GlobeNewswire Inc.
Dec 08, 2025 9:01 PM GMT
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined r